Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2026 |
|---|---|
| Revenue | — |
| R&D expense | $427,000 |
| Operating income | −$1.0M |
| Net income | −$1.0M |
| Cash & equivalents | $354,000 |
| Total debt | — |
| Operating cash flow | −$1.0M |
| Free cash flow | −$1.0M |
Company profile
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.